Benutzer: Gast  Login
Titel:

[MEK inhibitor-associated retinopathy under binimetinib treatment for cutaneous malignant melanoma].

Dokumenttyp:
Article; English Abstract; Journal Article
Autor(en):
Groselli, S; Heinrich, D; Lohmann, C P; Maier, M
Abstract:
The treatment options for patients with metastatic melanoma (MM) have been dramatically expanded in recent years with the approval of new drugs. The MEK (mitogen-acitvated protein kinase kinase) and BRAF (serine/threonine-protein kinase B-Raf coding gene) inhibitor combination therapy is currently part of the standard of care for stage IIIC/IV of BRAF mutant melanoma. The MEK inhibitor-associated retinopathy (MEKAR) is observed in patients with MM who are treated (or have been treated) with such...     »
Zeitschriftentitel:
Ophthalmologe
Jahr:
2021
Band / Volume:
118
Heft / Issue:
2
Seitenangaben Beitrag:
169-174
Volltext / DOI:
doi:10.1007/s00347-020-01089-3
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/32248296
Print-ISSN:
0941-293X
TUM Einrichtung:
Klinik und Poliklinik für Augenheilkunde
 BibTeX